By Dhirendra Tripathi
Investing.com – FibroGen (NASDAQ: FGEN ) stock slumped 44% Friday as an advisory committee of the Food and Drug Administration rejected the company’s proposed inhibitor to treat anemia in adult patients suffering from chronic kidney disease.
While the Committee's vote is not binding on the FDA, the agency considers its recommendations when making its decision.
FibroGen’s roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved in China, Japan, Chile, and South Korea for the treatment of anemia of CKD in both non-dialysis-dependent and dialysis-dependent adult patients.
Anemia of CKD is a condition in which people have insufficient red blood cells, which reduces oxygen delivery throughout the body.1 Anemia becomes increasingly common among patients with CKD as the disease progresses whether or not they are on dialysis.
FibroGen is collaborating with AstraZeneca on the development and commercialization of roxadustat for the potential treatment of anemia of CKD in the U.S., China, other markets in the Americas, in Australia/New Zealand, and Southeast Asia.
AstraZeneca (NASDAQ: AZN ) stock was unaffected by the news and traded up nearly 1%.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.